Conducting effective clinical trials in hematologic malignancies requires an understanding of a rapidly evolving treatment paradigm that is increasingly nuanced, complex, and patient-directed.

This white paper reviews considerations for biotech companies planning hematologic oncology clinical trials such as trial endpoints, designs, and data management, as well as patients' diversity and experiences.